People with rheumatoid arthritis were more satisfied with their treatment when they could choose between two medicines, a ...
Tech Times on MSN
FDA approves Ilumya for psoriatic arthritis treatment as only office-administered IL-23 inhibitor
Psoriatic arthritis treatment now includes Ilumya (tildrakizumab-asmn) after FDA approval on October 30, 2026. Sun Pharma ...
In a single-center study of 66 treatment-naïve rheumatoid arthritis patients, lower plasma interleukin-22 and higher tumor ...
Deucravacitinib treatment yields sustained improvements in joint symptoms and skin disease severity among patients with active psoriatic arthritis.
For patients with rheumatoid arthritis (RA), those choosing their own treatment have higher treatment satisfaction, better ...
13d
Knee treatment without surgery offers lasting pain relief for 80% of arthritis patients, study finds
A non-surgical knee osteoarthritis treatment uses dissolvable gelatin particles to block excess blood vessels, reducing ...
A promising new treatment for knee arthritis uses tiny, dissolvable particles to block abnormal blood vessels, easing inflammation and pain without joint replacement surgery. In a study of 194 ...
Paulick Report on MSN
Research in action: Investigating a long-lasting treatment for equine arthritis
Grayson-funded researchers examined how polyacrylamide hydrogel affects horses' pain responses and joint inflammation.
Knee osteoarthritis (OA) is the most common type of arthritis, affecting about 528 million adults worldwide. It is more than ...
Arthritis & Joint Pain Center of Rochester highlights individualized, non-surgical approaches to managing chronic knee ...
Scipher Medicine plans early physician access for PrismTcell, a blood test to predict abatacept response in rheumatoid ...
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharma" and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results